NCT02617017View on ClinicalTrials.gov

Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 17, 2016

Primary Completion Date

March 23, 2023

Study Completion Date

March 23, 2023

Conditions

Parkinson

Interventions

DRUG

Buspirone

Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)

DRUG

Placebo

Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)

Trial Locations (1)

94010

Henri Mondor Hospital, Créteil

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02617017 - Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease | Biotech Hunter | Biotech Hunter